THE N 1 COLLABORATIVE INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2022

Legal Domicile

Principal Officer

WINSTON YAN

Phone

7726789669

Tax Period

2023-01-01 to 2023-12-31

THE N 1 COLLABORATIVE INC, founded in 2022, is a small nonprofit in the Diseases & Disorders sector that reported $398K in total revenue in fiscal year 2023. Revenue surged 329% from the prior year, signaling strong growth momentum. The organization ran a surplus of $118K, a strong 30% operating margin.

Mission

OUR MISSION IS TO MAKE INDIVIDUALIZED MEDICINES ROUTINELY AND RAPIDLY ACCESSIBLE TO RARE DISEASE PATIENTS WORLDWIDE.

Program Service Accomplishments

Program 1

Expenses: $59,929

TO ESTABLISH STANDARDS AND ENSURE CONSISTENCY ACROSS DIVERSE INDIVIDUALIZED TREATMENT PROGRAMS WORLDWIDE. SPECIFIC EXAMPLE ACCOMPLISHMENT: BEST PRACTICES HAVE BEEN DISSEMINATED THROUGH COLLABORATIVE EFFORTS, INCLUDING WORKGROUPS, SEMINARS, PEER-REVIEWED PUBLICATIONS, AND IN-PERSON MEETINGS. THIS EXCHANGE OF KNOWLEDGE HAS DIRECTLY BENEFITTED OUR COMMUNITY OF 500 MEMBERS, COMPRISING ACADEMIC RESEARCHERS, CLINICIANS, PATIENTS, AND INDUSTRY STAKEHOLDERS. ADDITIONALLY, NON-MEMBERS SEEKING EDUCATIONAL RESOURCES FOR INDIVIDUALIZED MEDICINES CAN FREELY ACCESS THE INFORMATION.

Program 2

Expenses: $59,929

TO AGGREGATE AND DISSEMINATE PRECLINICAL AND CLINICAL DATA TO ENHANCE THE SAFETY AND EFFICACY OF INDIVIDUALIZED TREATMENTS AND SUPPORT REGULATORY DECISION-MAKING. SPECIFIC EXAMPLE: INITIATED PILOT...

TO AGGREGATE AND DISSEMINATE PRECLINICAL AND CLINICAL DATA TO ENHANCE THE SAFETY AND EFFICACY OF INDIVIDUALIZED TREATMENTS AND SUPPORT REGULATORY DECISION-MAKING. SPECIFIC EXAMPLE: INITIATED PILOT PROJECTS TO ESTABLISH PRECLINICAL AND CLINICAL DATABASES, AIMING TO IDENTIFY THE MINIMUM VIABLE STRUCTURE REQUIRED FOR SUCH DATABASES. THIS ENDEAVOR ALLOWED US TO GAIN INSIGHTS INTO THE TECHNICAL, REGULATORY AND LEGAL FRAMEWORKS ESSENTIAL FOR SUPPORTING THESE DATABASES. APPROXIMATELY THIRTY PEOPLE DIRECTLY BENEFITED FROM THE PILOT PROJECTS, WITH A SIGNIFICANT NUMBER OF INDIRECT BENEFICIARIES ANTICIPATED ONCE THE PILOT IS EXPANDED TO THE PUBLIC.

Program 3

Expenses: $13,317

TO FACILITATE CONNECTIONS AND COLLABORATION AMONG STAKEHOLDERS INVOLVED IN THE DEVELOPMENT OF INDIVIDUALIZED MEDICINES VIA A COLLABORATIVE PLATFORM WHERE STAKEHOLDERS OFFERING GOODS, SERVICES...

TO FACILITATE CONNECTIONS AND COLLABORATION AMONG STAKEHOLDERS INVOLVED IN THE DEVELOPMENT OF INDIVIDUALIZED MEDICINES VIA A COLLABORATIVE PLATFORM WHERE STAKEHOLDERS OFFERING GOODS, SERVICES, REFERRALS, AND SUPPORT CAN CONNECT WITH THOSE SEEKING THEM, THEREBY FOSTERING IMPROVED COMMUNICATION AND ADVANCEMENT WITHIN THE FIELD. SPECIFIC EXAMPLE ACCOMPLISHMENT: VALIDATED THE NECESSITY FOR THE DESCRIBED PLATFORM, INITIATED THE FORMULATION OF PROJECT SCOPES, ENGAGED IN DISCUSSIONS WITH KEY STAKEHOLDERS, AND BEGAN DEVELOPING INITIAL RESOURCES. APPROXIMATELY 20 PEOPLE DIRECTLY BENEFITED FROM INITIAL SCOPING ACTIVITIES, WITH A SIGNIFICANT NUMBER OF DIRECT AND INDIRECT BENEFICIARIES ANTICIPATED AS THE PROJECT DEVELOPS FURTHER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $397,502

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $397,502

Expense Breakdown

Grants Paid $0

Salaries & Benefits $198,432

Fundraising Expenses $50,443

Program Expenses $133,175

Other Expenses $81,175

TOTAL EXPENSES $279,607

Year-over-Year Comparison

	2023	2022	Change
Revenue	$397,502	$92,600	+3.3%
Expenses	$279,607	$98,411	+1.8%
Net Income	$117,895	$-5,811	-21.3%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
WINSTON YAN	PRESIDENT	5.00	Officer Director	$0	$0	$0
JULIA VITARELLO	SECRETARY	5.00	Officer Director	$0	$0	$0
TIM YU	TREASURER	5.00	Officer Director	$0	$0	$0
ANNEMIEKE AARTSMA-RUS	DIRECTOR	2.00	Director	$0	$0	$0
HOLM GRAESSNER	DIRECTOR	1.00	Director	$0	$0	$0
NICOLE BOICE	DIRECTOR	1.00	Director	$0	$0	$0
KEITH FLANAGAN	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	No data	No data	No data	No data
2023	$397,502	$279,607	$120,320	$117,895